Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian... von Vergote, I, du Bois, A, Floquet, A, Rau, J, Kim, J.-W, del Campo, J.M, Friedlander, M, Pignata, S, Fujiwara, K, Colombo, N, Mirza, M.R, Monk, B.J, Tsibulak, I, Calvert, P.M, Herzog, T.J, Hanker, L.C, Meunier, J, Lee, J.-Y, Bologna, A, Carrasco-Alfonso, M.J, Harter, P

Volltext

Cerclage during trachelectomy for early-stage cervical cancer von Davenport, S.M, Jackson, A.L, Herzog, T.J

Volltext

A state by state analysis of BRCA1 and BRCA2 testing in patients with ovarian cancer von Herzog, T.J, Saam, J, Arnell, C, Wenstrup, R.J

Volltext

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery... von Brady, M.F, Herzog, T.J, Sabbatini, P, Armstrong, D.K, Walker, J.L, Kim, B.G, Fujiwara, K, Tewari, K.S, O'Malley, D.M

Volltext

3Geriatric assessment and tolerance to chemotherapy in elderly women with ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study von Huang, H, Tew, W, Hurria, A.H, Lankes, H, DiSilvestro, P.A, Mannel, R.S, Beumer, J.H, Heugel, A, Herzog, T.J

Volltext

Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer von Lhommé, C, Monk, B.J, Coleman, R.L, Herzog, T.J, Navale, L, Warner, D.J, Fujiwara, K

Volltext

Comparative effectiveness of radical hysterectomy in elderly women with cervical cancer von Tergas, A.I, Lewin, S.N, Burke, W.M, Prendergast, E, Lu, Y.S, Herzog, T.J, Wright, J.D

Volltext

Surveillance testing in women following a diagnosis of early-stage endometrial cancer von Neugut, A, Tergas, A.I, Lewin, S.N, Burke, W.M, Lu, Y.S, Herzog, T.J, Hershman, D

Volltext

Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer von Zimmerman, L.D, Lewin, S.N, Tergas, A.I, Burke, W.M, Lu, Y.S, Herzog, T.J, Wright, J.D

Volltext

Patterns of Care in Locally Advanced Vulvar Carcinoma von Sharma, C.S, Deutsch, I, Chao, C, Lewin, S.N, Herzog, T.J, Xuming, S, Lu, Y, Wright, J.D

Volltext

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option von Buechel, M., Herzog, T.J., Westin, S.N., Coleman, R.L., Monk, B.J., Moore, K.N.

Volltext

Lymphadenectomy Influences the Utilization of Adjuvant Radiation Therapy in Early-stage Endometrial Cancer von Sharma, C.S, Deutsch, I, Burri, R.J, Chao, C, Lewin, S, Burke, W, Qiao, Y, Sun, X, Herzog, T.J, Wright, J.D

Volltext

594P The heterogeneic molecular landscape of ovarian cancer metastases (OCM) von Hadfield, M.J., Wu, S., Thaker, P.H., Farrell, A., Oberley, M., Jones, N., Herzog, T.J., Dizon, D.S.

Volltext

Opportunistic salpingectomy would significantly reduce ovarian cancer mortality and would reduce overall healthcare expenditures von Hughes, B.N., Herzog, T.J., Brown, J., Drury, L.K., Naumann, R.W.

Volltext

818TiP REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in... von Naumann, R.W., Gonzalez Martin, A., Herzog, T.J., Coleman, R.L., Ray-Coquard, I.L., Miller, R., Lu, L., Dokainish, H., Berman, C., Oaknin, A.

Volltext

The Effect of Surgeon and Hospital Volume on Outcomes and Cost for Laparoscopic Hysterectomy von Wallenstein, M.R, Kim, J.H, Burke, W.M, Lewin, S.N, Lu, Y-S, Herzog, T.J, Wright, J.D

Volltext

LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) w... von Monk, B.J., Oaknin, A., O'Malley, D.M., Wilson, M., Lorusso, D., Westin, S., Oza, A.M., Zagouri, F., Herzog, T.J., Mikheeva, O., Parkinson, C., Coleman, R.L., Lim, M.C., Chudecka-Glaz, A.M., Eskander, R.N., Bruchim, I., Ghamande, S., Despain, D., Fujiwara, K., Kristeleit, R.

Volltext

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) von Pothuri, B., Blank, S.V., Myers, T.K., Hines, J.F., Randall, L.M., O'Cearbhaill, R.E., Slomovitz, B.M., Eskander, R.N., Alvarez Secord, A., Coleman, R.L., Walker, J.L., Monk, B.J., Moore, K.N., O'Malley, D.M., Copeland, L.J., Herzog, T.J.

Volltext

750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with do... von Slomovitz, B.M., Raaschou-Jensen, N., Coleman, R.L., Gilbert, L., Powell, M.A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A.A., Ataseven, B., Black, D., Wymenga, M., Billingsley, C., Willmott, L.J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T.J., Mirza, M.R.

Volltext

Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis von Richardson, M.T., Kapp, D.S., Chan, J.E., Liang, S.Y., Mann, A.K., Monk, B.J., Herzog, T.J., Lakomy, D.S., Coleman, R.L., Chan, J.K.

Volltext